The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu
Open accessAbstract
Treatment of advanced breast cancer with autologous stem cell transplantation is limited by a high probability of disease relapse. In clinical trials, interleukin 2 (IL-2) alone can expand natural killer (NK) cells in vivo and increase their cytotoxic activity against breast cancer cell lines, but this increase is modest. Understanding the mechanisms that mediate NK cell lysis of breast cancer targets may lead to improvements of current immunotherapy strategies. NK cells from normal donors or patients receiving subcutaneous IL-2 were tested in cytotoxicity assays against five breast cancer cell lines. The role of adhesion molecules and antibodies that interact through Fc receptors on NK cells was explored. NK cell lysis of breast cancer targets is variable and is partially dependent on recognition through ICAM-1 and CD18. While blocking CD2 slightly decreased cytotoxicity, contrary to expectations, an antibody against CD58 (the ligand for CD2), failed to block killing and instead mediated an increased cytotoxicity that correlated with target density of CD58. The CD58 antibody-enhanced killing was dependent not only on FcRgammaIII but also on CD2 and ICAM-1/CD18. To further elucidate the mechanism of this CD58 antibody-dependent cellular cytotoxicity (ADCC), another antibody was tested. Trastuzumab (Herceptin), a humanized antibody against HER2/neu, mediated potent ADCC against all the HER2/neu positive breast cancer targets. Unlike CD58 antibody-mediated ADCC, Herceptin ADCC was minimally affected by blocking antibodies to CD2 or ICAM-1/CD18, which suggests a different mechanism of action. This study shows that multiple mechanisms are involved in NK cell lysis of breast cancer targets, that none of the targets are inherently resistant to killing, and that two distinct mechanisms of ADCC can target immunotherapy to breast cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 2 ICAM-1/CD18 interactions are involved in IL-2-activated NK lysis of breast cancer targets. IL-2-activated NK cells (96 6 2% CD56 1 / CD3 2 ) from normal donors were tested in cytotoxicity assays against breast cancer targets at an effector to target ratio of 4:1. Specific lysis was calculated for each target in the absence of antibody for T47D (79 6 3.4%), MDA-MB-231 (70 6 2.7%), BT-20 (45 6 9.3%), and SKBR-3 (53 6 9%). Data are presented as the percent of control with each antibody or combination as follows: [(% lysis with antibody 2 % lysis without antibody)/(% lysis without antibody)]. Each bar represents mean 6 SEM of 4 to 6 individual experiments analyzed in duplicate. There was significant inhibition of specific lysis for each breast cancer target involving recognition through b 2 integrins on NK cells. * p , 0.05.](https://figures.cochat.ai/paper-figures/a2b28518f52b41f5b009227774c1674a/natural-killer-cell-cytotoxicity-of-breast-cancer-targets-is-enhanced-by-two-figure-2.png)

![Figure 4 CD58-mediated antibody-dependent cellular cytotoxicity (ADCC) increases lytic activity in mononuclear cells (MNC) from patients receiving subcutaneous (SC) IL-2 but not in NK cells, which are CD16 negative. Peripheral blood mononuclear cells were obtained from patients treated for 14 to 28 days with SC IL-2 (1.75 3 10 6 U/m 2 /day) on a protocol to prevent relapse after autologous stem cell transplantation. Patient mononuclear cells (63 6 8% CD56 1 /CD3 2 , of which 87 6 2% expressed FcR g III [CD16]), without further IL-2 activation, were tested against the BT-20 breast cancer target at an effector to target ratio of 20:1. Cytotoxicity was significantly enhanced ( p , 0.05, n 5 4 patient samples performed in duplicate) when targets were pretreated with CD58 (AICD58) antibody compared to no antibody or IgG control. The requirement for FcR g III (CD16) on NK cells was tested further by generating NK cells from marrow CD34 1 progenitors in a long-term NK cell differentiation culture. IL-2 cultured NK cell progeny (97 6 1% CD56 1 /CD3 2 , of which 1.1 6 0.2% expressed FcR g III [CD16]) were tested against BT-20 at an effector to target ratio of 10:1. Unlike normal donor or patient-derived NK cells, the CD16 2 NK cells derived from marrow progenitors were unable to mediate ADCC when targets were pretreated with the CD58 (AICD58) antibody (n 5 4).](https://figures.cochat.ai/paper-figures/b744f13b39344bdbbf0c1594bf34add8/natural-killer-cell-cytotoxicity-of-breast-cancer-targets-is-enhanced-by-two-figure-4.png)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as well as CD33- and CD58-targeting mAbs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Cooley et al., 1999
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & HARMON, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2157::aid-cncr2820730821>3.0.co;2-1 · Cited by 2,135
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,003
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Antman, K. H., Rowlings, P. A., Vaughan, W. P., Pelz, C. J., Fay, J. W., Fields, K. K., Freytes, C. O., Gale, R. P., Hillner, B. E., Holland, H. K., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1870 · Cited by 323
Yokoyama, W. M. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80036-0 · Cited by 299
Signal Transduction during Natural Killer Cell Activation: Inside the Mind of a Killer
Leibson, P. J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80441-0 · Cited by 292
Kipps, T. J., Parham, P., Punt, J., & Herzenberg, L. A. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.1.1 · Cited by 248
Arousal and inhibition of human NK cells
Lanier, L. L., Corliss, B., & Phillips, J. H. (1997) · Immunological Reviews · doi:10.1111/j.1600-065x.1997.tb00947.x · Cited by 243
Miller, J., Alley, K., & McGlave, P. (1994) · Blood · doi:10.1182/blood.v83.9.2594.2594 · Cited by 213
Self-citationMiller, J. S., McCullar, V., Punzel, M., Lemischka, I. R., & Moore, K. A. (1999) · Blood · doi:10.1182/blood.v93.1.96 · Cited by 187
Self-citation
Research works printed but not linked: 3
- Or, 1998, Allogenic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation, Cytokines Cell Mol Ther, 4, 1
- Leibson, 1995, Viewpoint, Nat Immun, 14, 117
- Lichtenstein, 1990, Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells, Cancer Res, 50, 7364
Cited by
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
“HER2-targeted antibodies, including trastuzumab, have been shown to induce apoptosis in multiple breast cancer cell lines via antibody-dependent cellular cytotoxicity (ADCC)”
BackgroundMonoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 626
Romee, R., Foley, B., Lenvik, T., Wang, Y., Zhang, B., Ankarlo, D., Luo, X., Cooley, S., Verneris, M., Walcheck, B., et al. (2013) · Blood · doi:10.1182/blood-2012-04-425397 · Cited by 552
“Rituximab and trastuzumab, for example, have significantly improved the outcome for patients with CD20-expressing lymphomas or with Her2-expressing breast cancers, respectively.33-36 Therefore, shedding of CD16 may limit the efficacy of antibody therapy that involves ADCC.”
BackgroundInfluentialSelf-citationArnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V, Fermeaux, V, Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 545
“In addition, there is evidence supporting a role for trastuzumab in mediating antibodydependent cellular cytotoxicity (ADCC) (Cooley et al, 1999; Clynes et al, 2000; Carson et al, 2001; Repka et al, 2003; Gennari et al, 2004).”
BackgroundInfluential
Metadata
- Authors
- Cooley, S., Burns, L. J., Repka, T., & Miller, J. S.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Miller, Jeffrey S
- Venue
- Experimental Hematology
- Publisher
- Elsevier BV
- Published
- 1999-10
- Volume
- 27
- Issue
- 10
- Pages
- 1533-1541
- ISSN
- 0301-472X (ISSN-L)
- OpenAlex
- W2039609199
- Cited by
- 213
- References
- 36
- Citations by year
- 2025: 7 · 2024: 1 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 12 · 2019: 7 · 2018: 10 · 2017: 1 · 2016: 11 · 2015: 6 · 2014: 10 · 2013: 13 · 2012: 12
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 8286 d)
- Locations
- Experimental Hematology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- American Society of Hematology
- University of Minnesota
- National Institutes of Health
- National Cancer Institute (P01 CA65493, P01CA065493)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- natural killer cells, antibody-dependent cellular cytotoxicity, breast cancer, CD58, LFA-3, HER2/neu, trastuzumab, ICAM-1, CD18, CD2, Fc gamma receptor III, interleukin-2, adhesion molecules, immunotherapy
- MeSH terms
- Trastuzumab, Antibodies, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Breast Neoplasms, Cells, Cultured, Cytotoxicity Tests, Immunologic, Female, Flow Cytometry, Humans, Interleukin-2, Killer Cells, Natural, Lymphocyte Activation, Antigens, CD, Intercellular Adhesion Molecule-1, CD18 Antigens, CD58 Antigens, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. https://app.cochat.ai/papers/10.1016/s0301-472x(99)00089-2
- The paper
- Cooley, S., Burns, L. J., Repka, T., & Miller, J. S. (1999). Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Experimental Hematology. https://doi.org/10.1016/s0301-472x(99)00089-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.